Takeda and Halozyme sign global agreement for Enhanze technology
Takeda will make an upfront payment to Halozyme in addition to commercial milestone payments.
Drug Development
Santhera grants Agamree rights to Nxera for DMD
Octapharma receives FDA approval for new Fibryga formulation in AFD
Day One concludes Mersana Therapeutics acquisition
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
